Pharmacogenomics of Oral Antithrombotic Drugs

Author(s): Flavia Storelli, Youssef Daali, Jules Desmeules, Jean-Luc Reny, Pierre Fontana

Journal Name: Current Pharmaceutical Design

Volume 22 , Issue 13 , 2016

Become EABM
Become Reviewer
Call for Editor


Pharmacogenomics is a relatively recent yet rapidly expanding field of study examining how genetic variations influence responses to drugs. Antithrombotic drugs include the anticoagulant and antiplatelet compounds widely prescribed for the treatment and prevention of cardiovascular diseases. However, there is a large variability in response to antithrombotics, and this can modify the benefit/risk ratio of taking such medications. This variability can be explained by clinical factors such as age, sex, and drug-drug interactions, but also by genetic variants. In recent years, several genetic polymorphisms have been associated with variable biological responses to antithrombotics. Relevant polymorphisms related to antithrombotics have included target genes and genes that participate in the drugs’ pharmacokinetics. This article provides a comprehensive review of the published literature about the pharmacogenomics of antithrombotic drugs, including well-studied compounds such as vitamin K antagonists (e.g., warfarin, acenocoumarol, and phenprocoumon), aspirin, and clopidogrel, as well as more recently approved compounds such as prasugrel, ticagrelor, and direct oral anticoagulants.

Keywords: Pharmacogenomics, aspirin, P2Y12 antagonists, vitamin K antagonists, direct oral anticoagulants, response variability, personalized medicine, network biology

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 03 April, 2016
Page: [1933 - 1949]
Pages: 17
DOI: 10.2174/1381612822666151208122845
Price: $65

Article Metrics

PDF: 68
PRC: 1